DED is one of the most common ocular conditions in the United States and Europe. Inflammation plays a prominent role in the pathogenesis of DED, and the condition may eventually lead to damage to the ocular surface. Patients can present with different signs and symptoms, making diagnosis and disease management highly complex, particularly for patients with moderate to severe DED. Indeed, few therapies are approved specifically for the treatment of DED in the United States or Europe, with a high failure rate in clinical trials. As such, unmet need remains strong in DED, and multiple opportunities exist for novel therapies that offer improvements over existing options.

QUESTIONS ANSWERED

  • How do ophthalmologists rate Allergan’s Restasis and Takeda’s Xiidra (in the United States) and Santen’s Ikervis (in Europe) as performing on key treatment drivers and goals for moderate to severe DED?
  • Which attributes are key influencers, which have limited impact, and which are hidden opportunities for drug differentiation in moderate to severe DED?
  • What are the prevailing areas of unmet need and opportunity in the treatment of moderate to severe DED?
  • What trade-offs across key drug attributes and price are acceptable to ophthalmologists for a hypothetical new drug for moderate to severe DED?

CONTENT HIGHLIGHTS

Geographies: United States, France, Germany, United Kingdom

Primary Research: Survey of 63 U.S. and 31 European ophthalmologists

Key Drugs Covered: Restasis (U.S.), Xiidra (U.S.), Ikervis (Europe), Cequa (U.S.), KPI-121 0.25%, CyclASol, HL036, voclosporin ophthalmic solution

Key Metrics Included:

Target Product Profile (TPP) simulator based on conjoint analysis methodology.

Stated versus derived importance of product attributes on prescribing behavior.

Assessment of current drug performance against treatment drivers and goals.

Physician perceptions of unmet needs in the indication and related indications.

Analysis of remaining drug development opportunities.

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Table of contents

  • Dry Eye - Unmet Need - Detailed, Expanded Analysis (US/EU5)

Author(s): Himanshu Jain, M.S. Pharm

Himanshu joined the CNS / ophthalmology team at Decision Resources Group in 2016. He has authored content for psychiatry and ophthalmology (retinal / nonretinal) indications, including schizophrenia, age-related macular degeneration, diabetic retinopathy / diabetic macular edema, dry eye disease, glaucoma, and uveitis.

Himanshu has more than ten years of experience working in market research and consulting firms, and has managed multiple market assessment projects, including bottom-up forecasts, across multiple therapy areas. He holds a M.S. degree in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research in India and an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.


Related Reports

Dry Eye - Landscape & Forecast - Disease Landscape & Forecast

Dry eye disease (DED) is a chronic, inflammatory, and highly heterogeneous condition of the eye; it is also referred to as dry eye syndrome or keratoconjunctivi...

View Details

Dry Eye - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)

In dry eye disease (DED), the normal functioning of the tear film is disrupted, resulting in troublesome ocular symptoms such as eye burning, and presentin...

View Details

Dry Eye - Access & Reimbursement - Detailed, Expanded Analysis (US)

The U.S. market for dry eye disease (DED) therapies witnessed notable developments in 2019, including Novartis’s acquisition of Xiidra and the launch of S...

View Details